Abstract:Although antiretroviral therapy (ART) is undeniably effective at blocking HIV replication to levels below the detection limit of conventionally available assays [1,2] , neither early [3] nor prolonged treatment is sufficient to cure HIV infection [4–6] . Indeed, upon treatment interruption, plasma viral rebound occurs in majority of HIV-infected individuals within a relatively short time frame, around 14–21 days [7,8] , demonstrating that HIV persists despite ART. Historically, the quantification of HIV-infected cells relied mainly on either PCR-based methods measuring viral nucleic acids [9–11] and/or on viral outgrowth assays assessing viral competency [12,13] . These assessments supported the paradigm that viral persistence was primarily associated with quiescent yet inducible HIV infection of long-lived resting memory CD4 + T cells in the blood, referred to as the 'latent reservoir' [4,5,14] which was largely unchanging and stable over-time [6,15] . In contrast to peripheral blood, secondary lymphoid organs (such as the spleen, lymph nodes, and gut-associated lymphoid tissues), where viral replication predominantly occurs, remained less extensively investigated [16,17] . This was mainly attributed to two major reasons: limited accessibility to tissue samples from individuals on ART due to ethical considerations, and tissues were believed to harbor HIV-infected cells actively expressing HIV genes and viral transcripts, constituting an 'active reservoir' susceptible to elimination – either directly through viral cytopathic effects or through cell-mediated immunity [18] . However, recent studies have played a pivotal role in unravelling the complexity of the HIV reservoir in terms of its cellular composition, tissue distribution, and transcriptional activity [19] .

Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection

Research progress on HIV latency-reversing agents and its mechanism

HIV Persistence, Latency, and Cure Approaches: Where Are We Now?

The reservoir of latent HIV

Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure

Interventions during Early Infection: Opening a Window for an HIV Cure?

HIV-1 functional cure: will the dream come true?

HIV Reservoirs and Treatment Strategies toward Curing HIV Infection

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

Research Progress on Human Immunodeficiency Virus Type 1 Latent Infection Activator

The Rational Combination Strategy of Immunomodulatory Latency Reversing Agents and Novel Immunotherapy to Achieve HIV-1 Cure

Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1

Latency reversal and viral clearance to cure HIV-1

Targeting Viral Transcription for HIV Cure Strategies

Advancements in Developing Strategies for Sterilizing and Functional HIV Cures

The multifaceted nature of HIV tissue reservoirs

Research progress on human immunodeficiency virus reservoir and its eradication

Strategies for human immunodeficiency virus cure：current status and future prospects

HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing

Translational eradication approaches

HIV Tissue Reservoirs: Current Advances in Research